FS Development Corp.
Status: Deal Closed
U=S
| IPO Proceeds, $M | $120.75M |
|---|---|
| IPO Date | Aug 12, 2020 |
| CEO | Jim Tananbaum |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology |
| IPO Geography | Global |
| Target Company | Gemini Therapeutics |
| Deal Announced | Oct 15, 2020 |
| Deal Size, $M | $265.60M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Feb 3, 2021 |
| Amendment Vote | TBD |
| Closing Date | Feb 5, 2021 |
Formerly FSDC
GMTX
| Price | 1.35 |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on FS Development Corp.:
- Structure and cap table
- 7 directors & officers
- 20 filings and events
- 1 underwriters
- 5 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Jim Tananbaum | 57 | President, CEO and Director |
| Dennis Ryan | 65 | CFO |
| Michael Rome | 35 | Vice President and Director |
| Vikram Bajaj | 42 | Director |
| Robert Carey | 62 | Director |
| Daniel Dubin | 55 | Director |
| Deepa Pakianathan | 55 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Deal
Sign in to view merger details and deal financials.